HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPL-A830, an investigational KRAS-EGFR antibody-targeted therapy conjugate (ATTC), in a deal worth up to $1.295 billion.
Under the agreement announced on September 3, 2026, GSK will receive exclusive rights to develop and commercialize HMPL-A830 worldwide, excluding Mainland China, Hong Kong, Macau and Taiwan, where HUTCHMED will retain full development and commercialization rights.
The agreement includes an upfront payment of $110 million, with HUTCHMED eligible to receive an additional $1.185 billion in potential development, regulatory and commercial milestone payments, as well as tiered royalties on annual net sales.
Targeting KRAS and EGFR With a Single Conjugate
HMPL-A830 is described by HUTCHMED as a first-in-class KRAS-EGFR ATTC. The investigational therapy combines a highly selective KRAS small-molecule inhibitor payload with an anti-EGFR antibody.
The approach is designed to deliver the KRAS inhibitor selectively to EGFR-expressing tumors while simultaneously blocking EGFR and KRAS signaling. According to HUTCHMED, this dual mechanism could improve antitumor efficacy and durability while limiting toxicity associated with systemic delivery of small-molecule KRAS inhibitors.
Initial clinical development will focus on colorectal, pancreatic and lung cancers, tumor types in which KRAS alterations are particularly common.
HMPL-A830 is expected to enter clinical development in the second half of 2026. HUTCHMED will lead the global Phase 1 development program, registered as NCT07718581, while GSK will take responsibility for subsequent clinical development and commercialization outside the territories retained by HUTCHMED.
A New Class of Precision Oncology Medicines
Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, highlighted the significance of the partnership for the company’s ATTC platform:
“Our ATTCs combine antibodies with our proprietary small-molecule inhibitor payloads to deliver dual mechanisms of action.”
Cheng noted that HMPL-A830 is HUTCHMED’s third candidate from its ATTC platforms and the first to be licensed to a global partner, describing the agreement as an important step toward realizing the potential of this emerging class of precision oncology therapies.
Hesham Abdullah, Senior Vice President and Global Head of Oncology R&D at GSK, added that the agreement reflects GSK’s continued expansion in oncology.
“The dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care.”
He said GSK plans to work with HUTCHMED to advance the candidate through clinical development.
Expanding HUTCHMED’s ATTC Platform
HUTCHMED’s ATTC platform combines monoclonal antibodies with proprietary small-molecule inhibitor payloads using antibody-guided delivery. Unlike conventional antibody-drug conjugates that typically carry cytotoxic payloads, the platform is designed to deliver targeted small-molecule inhibitors directly to tumor cells.
HMPL-A830 follows two other candidates from HUTCHMED’s ATTC platform that have already moved into clinical development: HMPL-A251, targeting HER2 with a PI3K/PIKK inhibitor payload, and HMPL-A580, targeting EGFR using the same broader payload strategy.
As part of the new agreement, GSK will also receive a right of first negotiation for one earlier-stage ATTC candidate from HUTCHMED.
The transaction remains subject to customary closing conditions, including applicable antitrust regulatory reviews.
Read more on OncoDaily: China NMPA Conditionally Approves HUTCHMED’s ATLED (Fanregratinib) for FGFR2-Altered Intrahepatic Cholangiocarcinoma
